m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT00083
|
[1], [2], [3] | |||
: m6A sites
Direct
Enhancement
RNA modification
GRIA2
GRIA2
ADARB1
Methylation
: modification sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Double-stranded RNA-specific editase 1 (ADARB1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | RNA modification (RNAMod) >> Adenosine-to-Inosine editing (A-to-I) | ||||
| Epigenetic Regulator | Double-stranded RNA-specific editase 1 (ADARB1) | WRITER | View Details | ||
| Regulated Target | Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) | View Details | |||
| Crosstalk Relationship | m6A → A-to-I | Enhancement | |||
| Crosstalk Mechanism | m6A modification directly impacts RNA modification through modulating the expression level of RNA modification regulator | ||||
| Crosstalk Summary | METTL3 methylates Double-stranded RNA-specific editase 1 (ADARB1) mRNA, thereby enhancing its protein expression, which subsequently promotes ADARB1 mediated A-to-I RNA editing of the Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) transcript. | ||||
| Responsed Drug | E-2007 | ||||
| Cell Process | RNA editing | ||||
In-vitro Model |
MGG8 | Glioblastoma | Homo sapiens | CVCL_D1H4 | |
| HeLa | Endocervical adenocarcinoma | Homo sapiens | CVCL_0030 | ||
| SH-SY5Y | Neuroblastoma | Homo sapiens | CVCL_0019 | ||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| Glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) | 6 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
| E-2007 | Approved | [4] | ||
| Synonyms |
Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
Click to Show/Hide
|
|||
| MOA | Inhibitor | |||
| External Link | ||||
| Paliroden | Phase 2 | [5] | ||
| Synonyms |
SR-57667; SR-57667B
Click to Show/Hide
|
|||
| MOA | Modulator | |||
| External Link | ||||
| ATPO | Investigative | [6] | ||
| Synonyms |
252930-37-3; (R,S)-2-Amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid; 2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-1,2-oxazol-4-yl]propanoic acid; ATPO, solid; AC1NECDZ; Lopac0_000092; SCHEMBL4318475; CHEMBL265301; GTPL4141; DTXSID70404915; MolPort-003-940-289; HMS3261F20; HMS3260C06; Tox21_500589; Tox21_500092; MFCD03452828; LP00092; LP00589; CCG-204187; NCGC00261274-01; NCGC00260777-01; NCGC00015093-05; NCGC00015093-02; NCGC00093594-01; NCGC00015093-04; NCGC00093594-02; NCGC00015093-03; EU-0100092; A 7845
Click to Show/Hide
|
|||
| MOA | Antagonist | |||
| External Link | ||||
| (S)-5-fluorowillardiine | Investigative | [6] | ||
| Synonyms |
5-Fluorowillardiine; (S)-(-)-5-fluorowillardiine; 140187-23-1; FLUORO-WILLARDIINE; (S)-F-Willardiine; 2-AMINO-3-(5-FLUORO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID; CHEMBL123132; CHEBI:42549; 3-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-L-alanine; (S)-alpha-Amino-5-fluoro-3,4-dihydro-2,4-dioxo-1(2H)-pyrimmidinepropanoic acid; 3-(5-fluorouracil-1-yl)-L-alanine; (2S)-2-amino-3-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)propanoic acid; (S)-(-)-5-fluorowillardine
Click to Show/Hide
|
|||
| MOA | Agonist | |||
| Activity | Ki = 25.1 nM | |||
| External Link | ||||
| [3H]AMPA | Investigative | [6] | ||
| Synonyms |
alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ampa; 74341-63-2; 77521-29-0; (RS)-AMPA; AMPA (pharmaceutical); CHEMBL13378; CHEBI:34018; 4-Isoxazolepropanoic acid, alpha-amino-2,3-dihydro-5-methyl-3-oxo-; gamma-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; dl-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; (+-)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; D,L-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid
Click to Show/Hide
|
|||
| MOA | Agonist | |||
| External Link | ||||
| [3H]CNQX | Investigative | [6] | ||
| Synonyms |
6-Cyano-7-nitroquinoxaline-2,3-dione; CNQX; 115066-14-3; 7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile; UNII-6OTE87SCCW; FG 9065; 6OTE87SCCW; FG-9065; 6-Cyano-2,3-dihydroxy-7-nitroquinoxaline; CHEBI:34468; 1,4-dihydro-2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; 7-nitro-2,3-dioxo-1,4-dihydroquinoxaline-6-carbonitrile; 6-Quinoxalinecarbonitrile, 1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-; ST50405216; 2,3-dihydroxy-7-nitro-6-quinoxalinecarbonitrile; FG9065; AC1MWAKF; Tocris-0190; Biomol-NT_000200
Click to Show/Hide
|
|||
| MOA | Antagonist | |||
| External Link | ||||
References
: m6A sites
: modification sites